Curofy Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 01-01-2025
- Paid Up Capital ₹ 0.50 M
as on 01-01-2025
- Company Age 6 Year, 2 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.40 M
as on 01-01-2025
- Revenue -15.28%
(FY 2021)
- Profit -78.57%
(FY 2021)
- Ebitda -63.74%
(FY 2021)
- Net Worth 11.75%
(FY 2021)
- Total Assets 36.45%
(FY 2021)
About Curofy Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M.
The company currently has active open charges totaling ₹2.40 M.
Roshan Kumar, Bikky Rai, and Amandeep Singh serve as directors at the Company.
- CIN/LLPIN
U51909KA2018PTC118491
- Company No.
118491
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Nov 2018
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Curofy Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Roshan Kumar  | Director | 18-Mar-2021 | Current |
| Bikky Rai | Director | 13-Nov-2018 | Current |
| Amandeep Singh | Director | 18-Mar-2020 | Current |
Financial Performance of Curofy Pharmaceuticals.
Curofy Pharmaceuticals Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 15.28% decrease. The company also saw a substantial fall in profitability, with a 78.57% decrease in profit. The company's net worth Soared by an impressive increase of 11.75%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Curofy Pharmaceuticals?
In 2021, Curofy Pharmaceuticals had a promoter holding of 50.00% and a public holding of 50.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Shubh Laxmi Hospitality Private LimitedActive 2 years 2 months
Roshan Kumar and Amandeep Singh are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 18 Feb 2022 | ₹2.40 M | Open |
How Many Employees Work at Curofy Pharmaceuticals?
Unlock and access historical data on people associated with Curofy Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Curofy Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Curofy Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
